DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, D. A. P.
Right arrow Articles by Mobarek, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, D. A. P.
Right arrow Articles by Mobarek, A.

Vol. 29, Issue 4, Part 2, 606-610, April 2001


Interethnic Variability in Human Drug Responses

D. A. P. Evans, H. L. McLeod, S. Pritchard, M. Tariq, and A. Mobarek

Riyadh Armed Forces Hospital, Riyadh, Saudi Arabia (D.A.P.E., M.T., A.M.); and the University of Aberdeen, Aberdeen, United Kingdom (H.L.M., S.P.)


    Abstract
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

The scientific study of interethnic differences in responses to drugs has been extant for 80 years. Many of these differences have been described at the phenotypic level, and some have been explained by genetic factors. However, it is frequently difficult to disentangle accurately the hereditary and environmental influences in phenotypic comparisons. This is where the recent developments in knowledge of the genes responsible for drug receptors are starting to make a big impact. The beta 2 adrenoceptor is described; it has three genetic polymorphisms. The different genotypes influence responses to agonists such as albuterol (Salbutamol). New gene frequency data including those for Saudi Arabians, Indians, and Africans are shown. The expanding body of knowledge about genetic (and interethnic) variability in drug receptors is likely to be important in clinical medicine.



    Phenotypic Interethnic Comparisons
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

Early studies on interethnic differences in responses to medications were made in the U.S.A. Paskind (1921) investigated the effect of 0.002 mg of atropine sulfate hypodermically on 20 white and 20 colored men in Cook County Hospital, Chicago. Initial slowing of the heart rate reaching a maximum in 10 to 15 min was observed frequently in whites but not in colored subjects (Fig. 1; Table 1).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Change in pulse rate 10 min after 1/60 g of atropine hypodermically.

Constructed from data in Tables 3 and 4 of Paskind (1921).

                              
View this table:
[in this window]
[in a new window]
 

TABLE 1
Change of pulse rate 10 min after 1/60 g of atropine hypodermically in colored and white subjects

From Fisher's exact test, p = 0.0007, Paskind (1921).

Chen and Poth (1929) at Johns Hopkins (Baltimore, MD) measured the change in the transverse diameter of the pupil after the instillation of various mydriatics. Figure 2 shows a typical result 1 h after 10% l-ephedrine. The action was greatest in 10 Caucasians, intermediate in 10 Chinese, and least in 10 African Americans (Table 2).


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 2.   Mydriasis produced 1 h after the conjunctival instillation of 10% l-ephedrine.

Constructed from data in Table 7 of Chen and Poth (1929). CI INCTDPUP, confidence interval of the increase in the transverse diameter of the pupil. ETHNICG, ethnic groups. 1.00 = Caucasians, 2.00 = Chinese, 3.00 = African Americans.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 2
Univariate analysis of variance: Tests of between-subjects effects

Dependent variable: INCTDPUP. Computed from data in Table 7 of Chen and Poth (1929).

Since those early observations, the whole science of pharmacogenetics has come into being. Many interethnic differences in drug responses have been found to be caused by differences in the metabolic biotransformations of drugs. However, there are clear pointers that this is not the whole story.

Two examples have been selected to illustrate this point.
1.   In an investigation of the effect of morphine on Caucasians and Chinese, it was found that the former had significantly more respiratory depression than the latter at the same plasma morphine concentrations (Zhou et al., 1993, Fig. 6).
2.   A study by Olatunde and Evans (1982) used the QT interval (Goldberger and Goldberger, 1981, Figs. 6-10) of the electrocardiogram to measure the response to quinidine in Nigerians and Caucasian British healthy subjects. The QT interval was corrected for a heart rate of 60 beats per minute (QTc). Intraerythrocytic quinidine concentrations were measured after a single 200 mg oral dose. The healthy Nigerians showed higher levels (see Olatunde and Evans, 1982 Fig. 1). The increase in QTc interval from baseline was significantly greater in the healthy white subject (Olatunde and Evans, 1982, Fig. 2). The snag in the interpretation of this study is that the Nigerians were studied in Lagos and the whites in Liverpool. Thus, it is not clear whether the responsiveness of the heart was caused by genetic or environmental factors.



    The Elucidatory Power of Genetic Polymorphisms
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

In the field of drug metabolism many polymorphisms have been found wherein the same alleles occur in different frequencies in different ethnic groups. In other instances, different alleles have been found in different populations. Many examples show how these discoveries have shed light on interethnic variability in responses to drugs. Now that we can examine alleles directly, the obfuscations inherent in phenotypic studies of the kind referred to above can be circumvented. This is because there has been a fairly sudden advance in our knowledge of drug receptors, and it is becoming clear that they are subject to genetic variability in a manner similar to drug-metabolizing enzymes.



    The Challenge of Receptors
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

As pointed out in Rang et al. (1999), the protein targets for drug action on mammalian cells can be broadly divided into receptors, ion channels, enzymes, and carrier molecules. According to Rang et al. (1999), "Receptors differ from the others. They form the sensing elements in the system of chemical communications that coordinate the function of all the different cells in the body. The chemical messengers being hormones, transmitter substances or other mediators such as cytokines and growth factors".

The plethora of information accumulated in recent years can be seen in the 1999 Receptor & Ion Channel Nomenclature Supplement published with the March issue of TIPS (Alexander et al., 1999). It consists of 108 pages. Our knowledge of molecular genetics makes it likely that there are genetic variants for many of the receptors listed in this supplement; some will be polymorphic (see Alexander et al., 1999).

So the problem is one of selection. I have elected to concentrate on the beta 2-adrenergic receptor, whose encoding gene ADRB2 is on chromosome 5 (at 5q31-32) and which is genetically different from the beta 1- and beta 3-adrenoceptors, whose genes are ADRB1 and ADRB2 at 10q24-26 and 8p11-12, respectively (see Alexander et al., 1999).



    The beta 2-Adrenergic Receptor
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

This beta 2-AR1 is a typical metabotropic or 7-transmembrane-spanning receptor whose structure has been well studied (see Reihaus et al., 1993 as reproduced in Hall, 1996, Fig. 1; Rang et al., 1999, Figs. 2.3B and 2.7). This receptor has been found to exhibit genetic polymorphisms (Reihaus et al., 1993), the two most important being Gly/Arg at codon 16, and Glu/Gln at codon 27. Another polymorphism is at codon 164, but here the frequency of variant alleles is low.

There has been much interest in the relationships between these polymorphisms and various disorders, especially asthma (See Büscher et al., 1999), but this is not the subject of this discussion. Here the initial focus will mainly be on how these polymorphisms are related to the responsiveness of bronchial smooth muscle to beta -agonist drugs.

An in vitro study was carried out by Green et al. (1995) using human airway smooth muscle cells derived at autopsy from persons without pulmonary disorders. The response to a test stimulus following a 24-h exposure to isoproterenol showed that the homozygous Glu27 genotype conferred pronounced desensitization and down-regulation. (Green et al., 1995, Table 2).

In vivo studies have shown
1.   A significantly greater degree of bronchodilator desensitization of responses to formoterol with homozygous Gly16 than with homozygous Arg16 asthmatics (see Tan et al., 1997, Fig. 1).
2.   In a survey of FEV1 in asthmatic children, Martinez et al. (1997) found that Arg16 homozygotes were 5.3 times more responsive to albuterol than Gly16 homozygotes, and heterozygotes were 2.3 times more responsive (Martinez et al., 1997, Table 3).
3.   Albuterol concentrations in the blood were measured by Lima et al. (1999) in eight black and eight white asthmatics after oral ingestion of 8 mg. The percentage change in FEV1 was also measured sequentially. While there was no significant difference between the two groups in the blood albuterol concentrations, the airway responsiveness was markedly greater over 8 h in Arg16/Arg16 homozygotes than in the other two genotypes. No effect on albuterol-evoked FEV1 was observed at codon 27 (Lima et al., 1999, Fig. 1).

Other studies (discussed in detail by Lima et al., 1999) failed to show such a clear-cut difference between genotypes in their bronchodilation following albuterol administration. These studies probably differed because the drug was given by inhalation and the concentration acting on the bronchial beta 2 AR was variable. In the study by Lima et al. (1999), there was only a very small intersubject variability of plasma albuterol concentrations. These authors do not mention any interethnic differences in responsiveness within a single genotype (e.g., homozygous Arg16).



    The beta 2-Adrenoceptor Polymorphisms in Different Ethnic Groups
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

The data (published and unpublished) now available have been tabulated by my collaborator Dr. Howard A. McLeod and are shown in Table 3. There is a highly significant regression of Arg16 allele frequency on Gln27 allele frequency, which is further evidence in favor of linkage disequilibrium as previously noted, for example, by Martinez et al. (1997) and Dewar et al. (1998).

                              
View this table:
[in this window]
[in a new window]
 

TABLE 3
The distribution of beta 2-adrenoceptor alleles at codons 16 and 27 in various ethnic groups

The 13 data points obtained from Table 3 where there is information on both polymorphisms show wide variation and suggest the presence of two clusters, viz. Caucasians (1) and Africans and Chinese (2).

More data are available for the codon 27 than for the codon 16 polymorphism. There is a suggestion of the presence of a west-to-east cline (possibly stepped). The main conclusion, therefore, is that the Chinese and Africans have high Arg16 and Gln27 frequencies compared with Caucasians.



    Therapeutic Expectations
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

It might be expected that a Chinese population would require on average a much smaller dose of beta 2-AR agonist to achieve the same bronchodilatation as a Caucasian population. Furthermore, the Chinese might desensitize more readily. However, this may be an unwarranted assumption. The reason for caution in the extrapolation is that the beta 2-AR is only the first link in a catenary intracellular process (Fig. 3). The proteins involved in this sequential process may be subject to genetic variation.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Sequence of intracellular events that occur following binding of an agonist to the beta 2-adrenoceptor.



    Genetic Factors Influencing beta 2-Adrenoceptor Function in Human Airways
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

Genetic heterogeneity has been found in G proteins. Virchow et al. (1999) described a C825T polymorphism in GNB3, the gene encoding the G beta-3 subunit of heterotrimeric G proteins (OMIM 139130). The 825 T allele, associated with the expression of a shorter splice variant (G beta-3 subunit) gave enhanced signal transduction via pertussis toxin-sensitive G proteins. Neutrophils containing the variant had an enhanced chemotaxis and faster migration in response to stimulation with interleukin 8.

A codon 19 Arg/Cys genetic polymorphism was described by McGraw et al. (1998) in the 19-amino acid peptide that regulates the mRNA translation of the beta 2-AR molecule. This peptide is encoded by a short open reading frame termed the 5'-leader cistron (5'LC) situated 102 base pairs upstream from the beta 2-AR coding block. The expression of beta 2-AR was 72% higher in COS-7 cells bearing 5'LC Cys as compared with those possessing 5'LC Arg (McGraw et al., 1998, Fig. 4). In human airway smooth muscle cells beta 2-AR expression was twice as great in cells bearing 5'LC Cys (as compared with 5'LC Arg-bearing cells). A linkage disequilibrium was demonstrated between the 5'LC polymorphism and the beta 2-AR 16 and 27 polymorphisms described above. It seems possible that this new polymorphism may influence the response of bronchial smooth muscle to agonists, and it may exhibit interethnic variability.

It was pointed out by McGraw and Liggett (1997) that the principal mechanism of desensitization of beta 2-AR receptors is phosphorylation by beta-AR kinase or other closely related G protein-coupled receptor kinases.

Various cell types in the lung were found to have different activities of these kinases. For example, mast cells had much more than smooth muscle. These kinases could play a role in desensitization in vivo in response to beta 2-agonists. Genetic polymorphisms have not been described in these enzymes yet. It is quite possible that they exist, and if so their interethnic distribution may be variable.



    Influence of beta 2 Adrenergic Receptor Polymorphisms in Nonpulmonary Conditions
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

The beta 2-AR is a major lipolytic receptor in human fat cells. With the notion that the beta 2-AR polymorphisms might play a role in obesity, Large et al. (1997) genotyped 140 women with a large variation in body fat mass. The Glu27 homozygotes had an average fat mass excess of 20 kg (Large et al., 1997, Table 1). Neither allele at the Arg16Gly polymorphism was linked to obesity. An investigation of obese men did not give a similar result (Hellstrom et al., 1999). These findings in women will probably stimulate further work and may be applied to the known interethnic variability in obesity.

The codon 164 threonine/isoleucine polymorphism of beta 2-AR has not received much attention in humans because of the comparative rarity of the less frequent (isoleucine) allele. To investigate the functional significance of this polymorphism in the myocardium, Turki et al. (1996) prepared transgenic mice expressing 45 times the normal endogenous beta 2-AR. Mice with the mutant 164 Ile and mice with the wild-type threonine allele were studied. It was found in the mutant mice (as compared with the wild-type mice) that in vitro 1) the basal adenylyl cyclase activity was lower and 2) maximal isoproterenol stimulated activity was lower. It was found that in vivo 1) resting heart rate and dP/dt (max) were less and 2) responses to infused isoproterenol were similarly less.

Liggett et al. (1998) determined the codon 164 polymorphism in 259 patients with advanced heart failure due to ischemic heart disease or dilated cardiomyopathy and 212 healthy controls. The allele frequencies did not differ between the two populations, but the 1-year survival (Liggett et al., 1998, Fig. 2) in the 10 heterozygous Ile 164-carrying patients was only 42% compared with 76% for patients endowed with a wild-type beta 2-AR (relative risk, 3.69; p = 0.002). No interaction was noted with race (among other factors), but there were only 3 non-Caucasians in the 10 individuals in the Ile 164 group.

The studies briefly described above suggest that innovative therapies in many fields will have to take into account interethnic variations in receptors.



    Other Genetic Polymorphisms in Drug Receptors that may be of Clinical Interest
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

Alexander et al. (1999) reveals many receptors that could be relevant to clinical problems. Some are more attractive for investigation than others. I will call attention to one, namely, histamine 1 receptor HRH1 (OMIM 600167). The full structure of this gene, which is at chromosomal localization 3p 25, has been published (DeBacker et al., 1998).

Regarding histamine biotransformation, a C314T genetic polymorphism of histamine N-methyl transferase has been described (Yan et al., 1999). The T314 variant allele was found to be more common in asthmatics than in control subjects (allele frequencies, 0.19 versus 0.08; chi 2 = 12.40; p = 0.001; odds ratio = 2.62).

It is a common observation that some people become much more sleepy than others after the usual doses of both oral and inhaled antihistaminics. It would be of interest to know whether this phenomenon is influenced by the C314T polymorphism in histamine N-methyltransferase and by allelic variants of the HRH 1 when they come to light.



    A Voyage of Exploration
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

We are embarked on a voyage of exploration of the unknown with regard to the beta 2-AR polymorphisms. The key requirements in the area of clinical practice will be to conduct comparative experiments similar to those of Lima et al. (1999) in genotyped selected ethnic groups, e.g., Caucasians and Chinese, preferably in the same environment. Then the influence and importance of the polymorphisms in the two ethnic groups may be clarified.

The beta 2-AR is only one example wherein we happen to know more than about most drug receptor polymorphisms. Obviously, this is an exciting area of pharmacology and therapeutics and as yet its interethnic aspect has not received much attention.

On 23 July 1999 a survey was carried out of the ISI database for the combined terms "drug + receptor + human" for 1998 and 1999. A total of 766 article abstracts were found and examined. None dealt with any aspect of interethnic variability in receptors. So it would seem that the whole subject is ripe for development.



    "The Great Ocean of Truth"
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References

The concept of "diathesis" has been in the minds of the medical profession for many years (diathesis: a permanent, hereditary or acquired condition of the body which renders it liable to certain special diseases or affections; a constitutional predisposition or tendency; Willis, 1681). The idea was that persons with a particular constitution (often presumed to be hereditary) would be more liable than others to become ill when subjected to certain environmental influences. We are now at an interesting point in history because we have recently acquired the technology and we are beginning to see exactly how this interplay of genetic endowment and environmental factors works. This is true in fields other than pharmacogenetics and ecogenetics; for example, in understanding resistance and susceptibility to infective disorders (see Levin and Newport, 1999, who describe mutations in the interferon gamma receptor 1 as causing susceptibility to mycobacterial infections, and Allen et al., 1999, who describe resistance to cerebral malaria conferred by the presence of southeast Asian ovalocytosis band 3).

In the elucidation of the scientific basis of practical therapeutics, it seems that now is the time to intensify the study of genetic and interethnic variability of receptors. They could be regarded as important undiscovered constituents in Newton's "great ocean of truth" ("I do not know what I may appear to the world but to myself I seem to have been only like a boy playing on the seashore, and diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, while the great ocean of truth lay all undiscovered before me").

    Acknowledgments

Saad Al Harbi, Mohammed M Al Shamrani, Eileen MacCarthy, Anthony Illamas, Ben Centeno, and Rajakanna Jesuraja facilitated this work. The staff of the Medical Illustration Department, Riyadh Armed Forces Hospital prepared the figures. We are grateful to Jacqueline Pereira and Juliet Miquith for preparing this manuscript.

    Footnotes

The collection of blood samples from various ethnic groups was funded by the Research and Ethical committee of the Riyadh Armed Forces Hospital (Chairman Dr. Saleh M. Al Deeb M.D., FRCP Glasgow, FRCP Edinburgh).

Send reprint requests to: Emeritus Professor David A. Price Evans, M.D., D.Sc., Ph.D., FRCP, C123 Riyadh, Armed Forces Hospital, P.O. Box 7897, Riyadh 11159, Kingdom of Saudi Arabia. E-mail: dapevans{at}kfshhub.kshrc.edu.sa

    Abbreviations

Abbreviations used are: AR, adrenoceptor; 5'LC, 5'-leader cistron; FEV1, forced expiratory volume in 1 s.


    References
Top
Abstract
Phenotypic Interethnic...
The Elucidatory Power of...
The Challenge of Receptors
The beta 2-Adrenergic Receptor
The beta 2-Adrenoceptor...
Therapeutic Expectations
Genetic Factors Influencing beta 2-...
Influence of beta 2 Adrenergic...
Other Genetic Polymorphisms in...
A Voyage of Exploration
"The Great Ocean of...
References


0090-9556/01/2904-606-610$3.00
DMD, 29:606-610, 2001
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J Clin PharmacolHome page
K. Kim, J. A. Johnson, and H. Derendorf
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. L. Kirstein and P. A. Insel
Autonomic Nervous System Pharmacogenomics: A Progress Report
Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al.
A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness
J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, D. A. P.
Right arrow Articles by Mobarek, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, D. A. P.
Right arrow Articles by Mobarek, A.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition